- Salesforce expansion and growing payor coverage are starting to add to revenue growth momentum
- International sales met leadership expectations, except for Germany, which experienced residual softness from 2H18
- Surpassed 40,000 iFuse procedures performed by over 1,900 surgeons worldwide
- Launched iFuse Bedrock in the U.S.
Performance by Segment
ORTHOWORLD estimates segment sales and growth on an as-reported basis, as follows ($MM):
| 2Q19 | 2Q18 | % Chg | % Chg | |
| Spine | $16.3 | $13.7 | $2.7 | 19.4% |
| 1H19 | 1H18 | % Chg | % Chg | |
| Spine | $31.3 | $26.4 | $4.9 | 18.7% |
Sales by Geographic Region
ORTHOWORLD estimates geographic sales and growth as follows ($MM):
| 2Q19 | 2Q18 | % Chg | % Chg | |
| US | $15.0 | $12.2 | $2.9 | 23.5% |
| Ex-US | $1.3 | $1.5 | -$0.2 | -13.6% |
| Total | $16.3 | $13.7 | $2.7 | 19.4% |
Net Earnings Data
Net earnings, inclusive of all revenue, are as follows.
| Amt | % of Sales | |
| Sales | $16.3 | |
| Cost of Sales | -$1.6 | 9.7% |
| General and Admin | -$4.2 | 25.7% |
| Sales and Marketing | -$16.7 | 102.5% |
| R & D | -$1.9 | 11.9% |
| Other | -$0.5 | 3.2% |
| Net Earnings | -$8.7 | -53.0% |
Source: SI-BONE
Mike Evers is ORTHOWORLD’s Market Analyst. He can be reached by email.
Salesforce expansion and growing payor coverage are starting to add to revenue growth momentum
International sales met leadership expectations, except for Germany, which experienced residual softness from 2H18
Surpassed 40,000 iFuse procedures performed by over 1,900 surgeons worldwide
Launched iFuse Bedrock in the...
- Salesforce expansion and growing payor coverage are starting to add to revenue growth momentum
- International sales met leadership expectations, except for Germany, which experienced residual softness from 2H18
- Surpassed 40,000 iFuse procedures performed by over 1,900 surgeons worldwide
- Launched iFuse Bedrock in the U.S.
Performance by Segment
ORTHOWORLD estimates segment sales and growth on an as-reported basis, as follows ($MM):
| 2Q19 | 2Q18 | % Chg | % Chg | |
| Spine | $16.3 | $13.7 | $2.7 | 19.4% |
| 1H19 | 1H18 | % Chg | % Chg | |
| Spine | $31.3 | $26.4 | $4.9 | 18.7% |
Sales by Geographic Region
ORTHOWORLD estimates geographic sales and growth as follows ($MM):
| 2Q19 | 2Q18 | % Chg | % Chg | |
| US | $15.0 | $12.2 | $2.9 | 23.5% |
| Ex-US | $1.3 | $1.5 | -$0.2 | -13.6% |
| Total | $16.3 | $13.7 | $2.7 | 19.4% |
Net Earnings Data
Net earnings, inclusive of all revenue, are as follows.
| Amt | % of Sales | |
| Sales | $16.3 | |
| Cost of Sales | -$1.6 | 9.7% |
| General and Admin | -$4.2 | 25.7% |
| Sales and Marketing | -$16.7 | 102.5% |
| R & D | -$1.9 | 11.9% |
| Other | -$0.5 | 3.2% |
| Net Earnings | -$8.7 | -53.0% |
Source: SI-BONE
Mike Evers is ORTHOWORLD’s Market Analyst. He can be reached by email.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
ME
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.





